Brought to you by 
Icos co-promotes Solvay's AndroGel in the US
12 Nov 2021
Executive Summary
Icos has agreed to co-promote Solvay Pharmaceuticals' AndroGel (testosterone gel 1%) in the US as a replacement therapy for men with a deficiency or absence of natural testosterone. The agreement goes through 2006 and has a renewal option.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Concluded
Deal Type
-
Alliance
- Co-Promotion
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Icos co-promotes Solvay's AndroGel in the US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice